Nepsone is a preclinical-stage pharmaceutical company focused on developing innovative treatments for dermatological conditions linked to imbalances in the autonomic nervous system and immune system. The company's foundational theory in neuroimmunology posits that disruptions in neuropeptide activity contribute to conditions such as psoriasis. Nepsone's approach aims to harness the body's natural mechanisms to restore balance and alleviate these dermatological diseases. The company has received support from the Technology Development Fund of Rannís, which underscores its commitment to advancing research in this field.

Nepsone's drug discovery platform is designed to address a wide range of dermatological indications, with a particular emphasis on psoriasis as its lead indication, currently in the preclinical phase. The company is exploring both topical and systemic modalities for treatment. Additionally, Nepsone is in the research and discovery phase for other conditions such as alopecia areata and eczema, utilizing topical treatments. This strategic focus on leveraging existing biological pathways and developing novel therapies positions Nepsone as a potential leader in the dermatology space, particularly in areas where current treatment options are limited.

Iceland

Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system. Currently, these conditions are believed to originate in the immune system. Nepsone foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions. Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.

Nepsone

Company Details